Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

PaperCitations, authors & open-access status

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 352 citations, 2016 year and closed oa status.

352
Citations
2016
Year
closed
OA Status

Related on ScholarIQ

Ravi Salgia
Author
Lyudmila Bazhenova
Author
Kathryn A. Gold
Author
Alice T. Shaw
Author
The Lancet Oncology
Journal
Lung Cancer Treatments and Mutations
Topic
470M+ articles · free account